Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NYSE | Common Stock
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 29, 23 | 0.00 Increased by +100.00% | -0.46 Increased by +100.00% |
| Nov 10, 22 | -0.42 Increased by +57.14% | -0.44 Increased by +5.08% |
| Aug 15, 22 | -0.47 Decreased by -161.11% | -0.57 Increased by +17.54% |
| May 13, 22 | -0.93 Increased by +86.56% | -0.82 Decreased by -13.41% |
| Mar 30, 22 | -0.77 | -1.03 Increased by +25.24% |
| Nov 15, 21 | -0.98 | -0.74 Decreased by -32.43% |
| Aug 6, 21 | -0.18 | -0.80 Increased by +77.50% |
| Mar 31, 21 | -6.92 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | N/A Decreased by -100.00% | -45.09 M Decreased by -74.58 K% | - - |
| Jun 30, 22 | 0.00 Decreased by N/A% | -50.99 M Decreased by -14.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -100.67 M Decreased by -160.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -140.02 M Decreased by -191.66% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 3.00 Increased by +N/A% | -60.38 K Decreased by N/A% | Decreased by -2.01 M% - |
| Jun 30, 21 | 0.00 - | -44.67 M - | Decreased by N/A% - |
| Mar 31, 21 | 0.00 - | -38.70 M - | Decreased by N/A% - |
| Sep 30, 20 | 0.00 - | -48.01 M - | Decreased by N/A% - |